This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

DaunoXome

Almac Group

Drug Names(s): Cerubidine

Description: DaunoXome is the liposomal formulation of daunorubicin, an antibiotic that has antimitotic and cytotoxic activities. It inhibits DNA replication by binding to DNA between base pairs and it inhibits topoisomerase II, an enzyme involved in DNA replication.

Deal Structure: DaunoXome is sold in the U.S. by the Company's U.S. commercial team and by independent distributors abroad.

Almac and Galen
In April 2004, Galen was acquired by the Almac Group.

Galen and Gilead
In February 2012, Galen announced that the Company has acquired the chemotherapy agent, DaunoXome (daunorubicin citrate liposome injection) from Gilead Sciences. Galen US will market DaunoXome in the United States and will be made available through wholesalers.


DaunoXome News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug